Loading stock data…
AMRN
$14.89+0.69 (+4.86%)
After Hours$14.80-0.09 (-0.60%)· Last close Jun 9
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amarin Corporation plc in the Healthcare sector is trading at $14.89. Wall Street consensus targets $12.50 (2 analysts), implying a -16.1% move over the next 12 months. The stock is currently 29% below its 52-week high of $20.90, remaining 3.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply -16.1% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$14.89
Potential Downside
0%
Whystock Fair Value$14.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.48%
Volume
Today's trading volume
180,726
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were trending higher late Tuesday
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week higher late M
Generic drugmakers gain key victory in ‘skinny label’ patent case
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
Sector Update: Healthcare Stocks Climb Late Afternoon
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2%
Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case
(Updates with Amarin's response to a request for comment in the penultimate paragraph.) The US Su